GJA1 and cardiac arrhythmia: Our main findings were that, following prolonged administration, UDCA: (1) reduced ischaemia-induced arrhythmia incidence with no effect on reperfusion-induced arrhythmias, (2) attenuated ischaemia-induced CV slowing in the early stage with no effect on APD90 shortening, (3) maintained phosphorylation of Cx43 during acute ischaemia and (4) increased cardiac wavelength (WL) during acute ischaemia.